Deciphera Pharmaceuticals (DCPH) Research Coverage Started at B. Riley

B. Riley started coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report released on Friday, MarketBeat reports. The firm issued a buy rating and a $43.00 price target on the stock.

Several other research firms have also recently weighed in on DCPH. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, February 10th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $28.00 price objective on the stock in a research report on Tuesday, January 9th. Piper Jaffray Companies assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an overweight rating and a $35.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an overweight rating and a $30.00 price objective on the stock. Finally, JMP Securities assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an outperform rating and a $38.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $41.14.

Deciphera Pharmaceuticals (NASDAQ DCPH) opened at $29.71 on Friday. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $29.98.

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC grew its position in Deciphera Pharmaceuticals by 5.9% during the fourth quarter. Millennium Management LLC now owns 728,583 shares of the company’s stock valued at $16,517,000 after acquiring an additional 40,352 shares during the last quarter. Emerald Advisers Inc. PA grew its position in Deciphera Pharmaceuticals by 37.6% during the fourth quarter. Emerald Advisers Inc. PA now owns 482,626 shares of the company’s stock valued at $10,941,000 after acquiring an additional 131,886 shares during the last quarter. Orbimed Advisors LLC bought a new position in Deciphera Pharmaceuticals during the third quarter valued at approximately $7,487,000. BlackRock Inc. grew its position in Deciphera Pharmaceuticals by 3,989.6% during the fourth quarter. BlackRock Inc. now owns 363,483 shares of the company’s stock valued at $8,241,000 after acquiring an additional 354,595 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Deciphera Pharmaceuticals during the third quarter valued at approximately $5,548,000. Institutional investors own 45.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Deciphera Pharmaceuticals (DCPH) Research Coverage Started at B. Riley” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/20/deciphera-pharmaceuticals-dcph-research-coverage-started-at-b-riley.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply